| Heidi L Chichester, PT | |
|
2590 Peachtree Industrial Blvd, Suite D, Duluth, GA 30097-7909 | |
| (678) 667-3893 | |
| (678) 303-9388 |
| Full Name | Heidi L Chichester |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 26 Years |
| Location | 2590 Peachtree Industrial Blvd, Duluth, Georgia |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588789911 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alliance Sports Medicine Llc | 4981025269 | 8 |
News Archive
Scientists at the University of Portsmouth have won nearly half a million pounds to try and develop a way of allowing drugs to be delivered straight to the brain.
Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.
IGEN Networks Corp. is pleased to announce that it has signed a memorandum of understanding with Bio Business Development Corp. International, Inc. to negotiate the acquisition of the exclusive global distribution rights to the patented lateral-flow diagnostic testing platform technology for rapid detection of the infectious prion protein diseases.
Affymetrix, Inc. today announced that the U.S. District Court for the Western District of Wisconsin (the "Court") has granted the company's motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc., and has directed that the patent infringement lawsuits brought against the company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases closed.
Relatives and healthcare staff find it hard to diagnose pain levels in nursing home residents accurately, especially if they are cognitively impaired with illnesses such as dementia or unable to speak, according to a study in September issue of the Journal of Clinical Nursing.
› Verified 5 days ago
| Entity Name | Physical Therapy 360 Degrees |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1154795110 PECOS PAC ID: 6305147836 Enrollment ID: O20151229000350 |
News Archive
Scientists at the University of Portsmouth have won nearly half a million pounds to try and develop a way of allowing drugs to be delivered straight to the brain.
Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.
IGEN Networks Corp. is pleased to announce that it has signed a memorandum of understanding with Bio Business Development Corp. International, Inc. to negotiate the acquisition of the exclusive global distribution rights to the patented lateral-flow diagnostic testing platform technology for rapid detection of the infectious prion protein diseases.
Affymetrix, Inc. today announced that the U.S. District Court for the Western District of Wisconsin (the "Court") has granted the company's motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc., and has directed that the patent infringement lawsuits brought against the company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases closed.
Relatives and healthcare staff find it hard to diagnose pain levels in nursing home residents accurately, especially if they are cognitively impaired with illnesses such as dementia or unable to speak, according to a study in September issue of the Journal of Clinical Nursing.
› Verified 5 days ago
| Entity Name | Alliance Sports Medicine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841825122 PECOS PAC ID: 4981025269 Enrollment ID: O20200522002327 |
News Archive
Scientists at the University of Portsmouth have won nearly half a million pounds to try and develop a way of allowing drugs to be delivered straight to the brain.
Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.
IGEN Networks Corp. is pleased to announce that it has signed a memorandum of understanding with Bio Business Development Corp. International, Inc. to negotiate the acquisition of the exclusive global distribution rights to the patented lateral-flow diagnostic testing platform technology for rapid detection of the infectious prion protein diseases.
Affymetrix, Inc. today announced that the U.S. District Court for the Western District of Wisconsin (the "Court") has granted the company's motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc., and has directed that the patent infringement lawsuits brought against the company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases closed.
Relatives and healthcare staff find it hard to diagnose pain levels in nursing home residents accurately, especially if they are cognitively impaired with illnesses such as dementia or unable to speak, according to a study in September issue of the Journal of Clinical Nursing.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heidi L Chichester, PT 2590 Peachtree Industrial Blvd, Suite D, Duluth, GA 30097-7909 Ph: (678) 667-3893 | Heidi L Chichester, PT 2590 Peachtree Industrial Blvd, Suite D, Duluth, GA 30097-7909 Ph: (678) 667-3893 |
News Archive
Scientists at the University of Portsmouth have won nearly half a million pounds to try and develop a way of allowing drugs to be delivered straight to the brain.
Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.
IGEN Networks Corp. is pleased to announce that it has signed a memorandum of understanding with Bio Business Development Corp. International, Inc. to negotiate the acquisition of the exclusive global distribution rights to the patented lateral-flow diagnostic testing platform technology for rapid detection of the infectious prion protein diseases.
Affymetrix, Inc. today announced that the U.S. District Court for the Western District of Wisconsin (the "Court") has granted the company's motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc., and has directed that the patent infringement lawsuits brought against the company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases closed.
Relatives and healthcare staff find it hard to diagnose pain levels in nursing home residents accurately, especially if they are cognitively impaired with illnesses such as dementia or unable to speak, according to a study in September issue of the Journal of Clinical Nursing.
› Verified 5 days ago